Eterobarb (Antilon) is a
barbiturate derivative. It has mainly
anticonvulsant action with less
sedative effects than the closely related compound
phenobarbital. It saw reasonable success in clinical trials, but is not in widespread medical use.[1][2]
^Gallagher BB, Baumel IP, Woodbury SG, Dimicco JA (May 1975). "Clinical evaluation of eterobarb, a new anticonvulsant drug". Neurology. 25 (5): 399–404.
doi:
10.1212/wnl.25.5.399.
PMID1094318.
S2CID35510833.
^Smith DB, Goldstein SG, Roomet A (1986). "A comparison of the toxicity effects of the anticonvulsant eterobarb (antilon, DMMP) and phenobarbital in normal human volunteers". Epilepsia. 27 (2): 149–55.
doi:
10.1111/j.1528-1157.1986.tb03518.x.
PMID3956454.
S2CID20206800.
^Vida JA, Wilber WR, Reinhard JF (March 1971). "Anticonvulsants. 2. Acyloxymethyl and halomethyl derivatives of barbituric acid and diphenylhydantoin". Journal of Medicinal Chemistry. 14 (3): 187–9.
doi:
10.1021/jm00285a002.
PMID5552206.